BioCentury
ARTICLE | Company News

University of Toronto, Advanced Proteome Therapeutics deal

October 24, 2016 7:00 AM UTC

The university’s Toronto Recombinant Antibody Centre (TRAC) granted Advanced Proteome an exclusive option to license preclinical oncology antibody candidates against an undisclosed target to develop antibody-drug conjugates (ADCs) using Advanced Proteome’s protein conjugation technology. The partners will conduct joint research to evaluate the ADCs. ...